You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 16, 2025

Astrazeneca Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Astrazeneca

Drugs and US Patents for Astrazeneca

Showing 1 to 5 of 5 entries

Expired US Patents for Astrazeneca

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 6,858,576 ⤷  Try for Free
Astrazeneca DURANEST epinephrine bitartrate; etidocaine hydrochloride INJECTABLE;INJECTION 017751-006 Approved Prior to Jan 1, 1982 3,812,147 ⤷  Try for Free
Astrazeneca NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022101-001 Feb 27, 2008 5,877,192*PED ⤷  Try for Free
Astrazeneca Lp NEXIUM 24HR esomeprazole magnesium TABLET, DELAYED RELEASE;ORAL 207920-001 Nov 23, 2015 6,428,810*PED ⤷  Try for Free
Astrazeneca Ab QTERN dapagliflozin; saxagliptin hydrochloride TABLET;ORAL 209091-001 Feb 27, 2017 RE44186 ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 5 of 5 entries
Paragraph IV (Patent) Challenges for ASTRAZENECA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 20 mg/vial and 40 mg/vial ➤ Subscribe 2009-11-23
➤ Subscribe Injection 250 mg/mL, 1.2 mL and 2.4 mL prefilled syringe ➤ Subscribe 2014-06-11
➤ Subscribe Inhalation Suspension 0.25 mg/2 mL and 0.5 mg/2 mL ➤ Subscribe 2005-09-15
➤ Subscribe HydrochlorideExtended-release Tablets 2.5 mg/1000 mg ➤ Subscribe 2018-10-29
➤ Subscribe Delayed-release Capsules 20 mg ➤ Subscribe 2007-03-19
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2008-06-18
➤ Subscribe Tablets 200 mg and 300 mg ➤ Subscribe 2008-06-12
➤ Subscribe Tablets 90 mg ➤ Subscribe 2015-07-20
➤ Subscribe Tablets 5 mg, 10 mg, 20 mg and 40 mg ➤ Subscribe 2007-08-13
➤ Subscribe Nasal Spray 0.032 mg (32 mcg)/spray ➤ Subscribe 2007-05-14
➤ Subscribe Tablets 25 mg ➤ Subscribe 2005-08-12
➤ Subscribe Delayed-release for Oral Suspension 2.5 mg and 5 mg ➤ Subscribe 2018-09-24
➤ Subscribe Tablets 100 mg, 200 mg and 300 mg ➤ Subscribe 2006-02-21
➤ Subscribe Injection 50 mg/mL, 2.5 mL and 5 mL syringe ➤ Subscribe 2009-10-01
➤ Subscribe Extended-release Tablets 5 mg/500 mg, 2.5 mg/1000 mg, and 5 mg/1000 mg ➤ Subscribe 2013-07-31
➤ Subscribe Inhalation Suspension 1 mg/2 mL ➤ Subscribe 2010-05-28
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2013-07-31
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2012-03-30
➤ Subscribe Extended-release Tablets 150 mg ➤ Subscribe 2008-11-17
➤ Subscribe Extended-release Tablets 50 mg ➤ Subscribe 2008-10-17
➤ Subscribe Tablets 60 mg ➤ Subscribe 2015-09-30
➤ Subscribe Tablets 500 mcg ➤ Subscribe 2015-03-02
➤ Subscribe Delayed-release 20 mg and 40 mg ➤ Subscribe 2005-08-05
➤ Subscribe Tablets 50 mg, 150 mg and 400 mg ➤ Subscribe 2007-02-12

Supplementary Protection Certificates for Astrazeneca Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
2734522 2190009-7 Sweden ⤷  Try for Free PRODUCT NAME: ACALABRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1479 20201106
1685839 92292 Luxembourg ⤷  Try for Free PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1532149 CA 2013 00001 Denmark ⤷  Try for Free PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
2734522 CA 2021 00007 Denmark ⤷  Try for Free PRODUCT NAME: ACALABRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1479 20201106
1606261 PA2010010,C1606261 Lithuania ⤷  Try for Free PRODUCT NAME: ROFLUMILASTUM; REGISTRATION NO/DATE: EU/1/10/636/001-003 20100705
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 5 of 5 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

AstraZeneca's Competitive Landscape: Market Position, Strengths, and Strategic Insights

In the ever-evolving pharmaceutical industry, AstraZeneca stands as a formidable player, consistently pushing the boundaries of innovation and growth. As we delve into the competitive landscape surrounding this pharmaceutical giant, we'll explore its market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

AstraZeneca's Market Position

AstraZeneca has solidified its position as a leading global biopharmaceutical company, known for its innovative approach to drug discovery and development[2]. With operations spanning over 100 countries, the company has established a strong global presence, allowing it to tap into diverse markets and cater to a broad range of patient needs[2].

Revenue Growth and Future Ambitions

AstraZeneca's market position is further strengthened by its impressive revenue growth. In 2023, the company reported total revenue of $45.8 billion, up from $44.4 billion in the previous year[1]. This growth trajectory has set the stage for even more ambitious goals. AstraZeneca has unveiled its bold vision to achieve $80 billion in total revenue by 2030, nearly doubling its current figures[1].

"Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030." - Pascal Soriot, Chief Executive Officer, AstraZeneca[1]

This ambitious target underscores AstraZeneca's confidence in its pipeline and strategic direction, positioning it as a company with significant growth potential in the coming years.

Global Market Share

AstraZeneca's global market share is substantial, with the company ranking 8th globally based on prescription drug sales in 2023[5]. This positioning places AstraZeneca among the top-tier pharmaceutical companies worldwide, competing with industry giants like Pfizer, Merck, and GlaxoSmithKline.

AstraZeneca's Key Strengths

AstraZeneca's competitive edge in the pharmaceutical landscape is built on several key strengths that set it apart from its rivals.

Strong Product Portfolio

One of AstraZeneca's primary strengths lies in its robust and diverse product portfolio. The company boasts several blockbuster drugs across various therapeutic areas, including oncology, cardiovascular, renal, metabolism, respiratory, and immunology[3]. This diversification not only contributes to the company's financial stability but also positions it to address a wide range of medical needs.

Robust Research and Development Pipeline

AstraZeneca's commitment to innovation is evident in its strong R&D pipeline. The company invests heavily in research and development, with spending well above 20% of its revenues on R&D projects[5]. This focus on innovation has resulted in a pipeline of over 60 molecules in clinical development[3], promising a steady stream of new products in the coming years.

Global Presence and Market Reach

With operations in over 100 countries, AstraZeneca's global footprint is a significant strength[2]. This extensive reach allows the company to navigate diverse regulatory environments, tap into emerging markets, and maintain a strong presence in established pharmaceutical markets.

Strategic Partnerships and Collaborations

AstraZeneca has fostered strategic partnerships with academic institutions, research organizations, and other pharmaceutical companies[2]. These collaborations enhance the company's capabilities, accelerate drug development processes, and provide access to cutting-edge technologies and expertise.

Strategic Insights: AstraZeneca's Path Forward

AstraZeneca's strategic direction is shaped by several key insights and initiatives that are likely to drive its future growth and competitive position.

Focus on High-Growth Therapeutic Areas

AstraZeneca has strategically focused on high-growth therapeutic areas, particularly oncology. The company's oncology portfolio has shown impressive growth, with sales increasing by 20% in 2023[9]. This focus on areas with significant unmet medical needs positions AstraZeneca to capture growing market segments.

Emphasis on Personalized Medicine

AstraZeneca is at the forefront of personalized medicine, developing treatments tailored to individual patient profiles[2]. This approach not only improves patient outcomes but also differentiates AstraZeneca in an increasingly competitive market.

Expansion into Rare Diseases

The $39 billion acquisition of Alexion in 2021 marked AstraZeneca's strategic entry into the rare disease market[9]. This move has diversified the company's portfolio and opened up new growth opportunities in a specialized and potentially lucrative segment of the pharmaceutical industry.

Commitment to Sustainability

AstraZeneca's focus on sustainability and corporate social responsibility resonates with consumers and investors alike[2]. This commitment not only enhances the company's reputation but also aligns with growing global emphasis on sustainable business practices.

Navigating Challenges in the Competitive Landscape

While AstraZeneca's position is strong, the company faces several challenges in the competitive pharmaceutical landscape.

Patent Expirations

Like many pharmaceutical companies, AstraZeneca must navigate the challenge of patent expirations for key products. The upcoming patent expirations for blockbuster drugs like Farxiga and Tagrisso present a significant hurdle in maintaining revenue growth[9].

Intense Competition in Key Therapeutic Areas

AstraZeneca faces stiff competition in several of its key therapeutic areas, particularly in oncology[8]. As a relatively late entrant in some fields, the company must continually innovate to differentiate its offerings and capture market share.

Regulatory and Pricing Pressures

The pharmaceutical industry as a whole faces increasing regulatory scrutiny and pressure to control drug prices. AstraZeneca must navigate these challenges while maintaining profitability and funding its extensive R&D efforts.

AstraZeneca's Competitive Advantages

Several factors contribute to AstraZeneca's competitive edge in the pharmaceutical market:

Strong Brand Reputation

AstraZeneca has built a strong brand reputation over the years, known for delivering high-quality, innovative medicines[2]. This reputation instills trust among healthcare professionals, patients, and investors.

Diverse Geographic Revenue Stream

AstraZeneca's revenue is well-distributed geographically, with significant contributions from various regions. In 2023, the US market accounted for 44% of the company's total revenue, highlighting the importance of this key market while also demonstrating the company's global reach[10].

Effective Corporate Strategy

AstraZeneca's corporate strategy effectively aligns with changing market dynamics, focusing on areas with high unmet medical needs[7]. This strategic alignment positions the company to capitalize on emerging opportunities in the pharmaceutical landscape.

Future Outlook and Growth Strategies

Looking ahead, AstraZeneca's growth strategy centers on several key initiatives:

Ambitious Product Launch Plans

AstraZeneca plans to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues[1]. This aggressive pipeline strategy is central to the company's ambitious revenue growth targets.

Continued Investment in R&D

AstraZeneca remains committed to investing heavily in research and development, maintaining its position at the forefront of pharmaceutical innovation[5].

Strategic M&A and Partnerships

While organic growth is a priority, AstraZeneca's history suggests that strategic mergers, acquisitions, and partnerships will continue to play a role in expanding its capabilities and market reach[9].

Expansion in Emerging Markets

AstraZeneca is likely to continue its focus on expanding its presence in emerging markets, capitalizing on growing healthcare needs and increasing access to medicines in these regions.

Key Takeaways

  • AstraZeneca holds a strong market position, ranking 8th globally in prescription drug sales.
  • The company aims to achieve $80 billion in total revenue by 2030, driven by a robust pipeline and strategic focus on high-growth therapeutic areas.
  • Key strengths include a diverse product portfolio, strong R&D capabilities, global presence, and strategic partnerships.
  • Challenges include patent expirations, intense competition, and regulatory pressures.
  • Future growth strategies center on ambitious product launches, continued R&D investment, strategic M&A, and expansion in emerging markets.

FAQs

  1. What is AstraZeneca's current market position in the pharmaceutical industry? AstraZeneca ranks 8th globally based on prescription drug sales as of 2023, with a strong presence in key therapeutic areas such as oncology, cardiovascular, and respiratory diseases.

  2. How does AstraZeneca plan to achieve its $80 billion revenue target by 2030? AstraZeneca plans to launch 20 new medicines by 2030, many with potential for over $5 billion in peak year revenues. The company will also continue investing in R&D and focus on high-growth therapeutic areas.

  3. What are some of AstraZeneca's key competitive advantages? AstraZeneca's competitive advantages include a strong product portfolio, robust R&D pipeline, global presence, strategic partnerships, and a focus on personalized medicine and rare diseases.

  4. How is AstraZeneca addressing the challenge of patent expirations? While specific strategies aren't detailed in the provided information, pharmaceutical companies typically address patent expirations through developing new drugs, extending existing patents through new formulations or indications, and diversifying their product portfolio.

  5. What role does sustainability play in AstraZeneca's strategy? AstraZeneca has a strong commitment to sustainability and corporate social responsibility, which enhances its reputation and aligns with growing global emphasis on sustainable business practices.

Sources cited: [1] https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html [2] https://canvasbusinessmodel.com/blogs/competitors/astrazeneca-competitive-landscape [3] https://www.studentsassignmenthelp.co.uk/answers/astrazeneca-uk-swot-analysis/ [5] https://www.statista.com/topics/7584/astrazeneca/ [7] https://thestrategystory.com/blog/astrazeneca-swot-analysis/ [8] https://www.investing.com/news/swot-analysis/astrazenecas-swot-analysis-pharma-giants-stock-poised-for-growth-amid-challenges-93CH-3838445 [9] https://www.fiercepharma.com/pharma/astrazeneca-fast-track-growth-sets-target-revenue-80b-2030 [10] https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.